These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 35563425)

  • 1. Plasma Aldo-Keto Reductase Family 1 Member B10 as a Biomarker Performs Well in the Diagnosis of Nonalcoholic Steatohepatitis and Fibrosis.
    Park A; Choi SJ; Park S; Kim SM; Lee HE; Joo M; Kim KK; Kim D; Chung DH; Im JB; Jung J; Shin SK; Oh BC; Choi C; Nam S; Lee DH
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis.
    Kanno M; Kawaguchi K; Honda M; Horii R; Takatori H; Shimakami T; Kitamura K; Arai K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Kaneko S
    J Gastroenterol; 2019 Jun; 54(6):549-557. PubMed ID: 30707282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Large-Scale Multicenter Study Validates Aldo-Keto Reductase Family 1 Member B10 as a Prevalent Serum Marker for Detection of Hepatocellular Carcinoma.
    Ye X; Li C; Zu X; Lin M; Liu Q; Liu J; Xu G; Chen Z; Xu Y; Liu L; Luo D; Cao Z; Shi G; Feng Z; Deng H; Liao Q; Cai C; Liao DF; Wang J; Jin J; Cao D
    Hepatology; 2019 Jun; 69(6):2489-2501. PubMed ID: 30672601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Composite Blood Biomarker Including AKR1B10 and Cytokeratin 18 for Progressive Types of Nonalcoholic Fatty Liver Disease.
    Choi SJ; Yoon S; Kim KK; Kim D; Lee HE; Kim KG; Shin SK; Park IB; Kim SM; Lee DH
    Diabetes Metab J; 2024 Feb; ():. PubMed ID: 38311058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of AKR1B10 and AKR1B8 in the pathogenesis of non-alcoholic steatohepatitis (NASH) in mouse.
    Rajak S; Gupta P; Anjum B; Raza S; Tewari A; Ghosh S; Tripathi M; Singh BK; Sinha RA
    Biochim Biophys Acta Mol Basis Dis; 2022 Apr; 1868(4):166319. PubMed ID: 34954342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.
    Bril F; McPhaul MJ; Caulfield MP; Clark VC; Soldevilla-Pico C; Firpi-Morell RJ; Lai J; Shiffman D; Rowland CM; Cusi K
    Diabetes Care; 2020 Feb; 43(2):290-297. PubMed ID: 31604692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease.
    Qadri S; Ahlholm N; Lønsmann I; Pellegrini P; Poikola A; Luukkonen PK; Porthan K; Juuti A; Sammalkorpi H; Penttilä AK; D'Ambrosio R; Soardo G; Leeming DJ; Karsdal M; Arola J; Kechagias S; Pelusi S; Ekstedt M; Valenti L; Hagström H; Yki-Järvinen H
    J Clin Endocrinol Metab; 2022 Apr; 107(5):e2008-e2020. PubMed ID: 34971370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of cytotoxic chemotherapy on aldo-keto reductase family 1 member B10 expression.
    Robinson K; Cao Z; Delfino K; Cao D; Rao K
    J Int Med Res; 2023 Jun; 51(6):3000605231179317. PubMed ID: 37389562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a role for serum aldo-keto reductase family 1 member B10 in early detection of hepatocellular carcinoma.
    Han C; Gao L; Bai H; Dou X
    Oncol Lett; 2018 Dec; 16(6):7123-7130. PubMed ID: 30546447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis.
    Kozumi K; Kodama T; Murai H; Sakane S; Govaere O; Cockell S; Motooka D; Kakita N; Yamada Y; Kondo Y; Tahata Y; Yamada R; Hikita H; Sakamori R; Kamada Y; Daly AK; Anstee QM; Tatsumi T; Morii E; Takehara T
    Hepatology; 2021 Nov; 74(5):2452-2466. PubMed ID: 34105780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of aldo-keto reductase family 1 member B10 on the risk of hepatitis C virus-related hepatocellular carcinoma.
    Sato S; Genda T; Ichida T; Murata A; Tsuzura H; Narita Y; Kanemitsu Y; Ishikawa S; Kikuchi T; Mori M; Hirano K; Iijima K; Wada R; Nagahara A; Watanabe S
    J Gastroenterol Hepatol; 2016 Jul; 31(7):1315-22. PubMed ID: 26758591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting Non-Alcoholic Fatty Liver Disease Progression and Immune Deregulations by Specific Gene Expression Patterns.
    Zeng F; Zhang Y; Han X; Zeng M; Gao Y; Weng J
    Front Immunol; 2020; 11():609900. PubMed ID: 33574818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
    Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accurate liquid biopsy for the diagnosis of non-alcoholic steatohepatitis and liver fibrosis.
    Angelini G; Panunzi S; Castagneto-Gissey L; Pellicanò F; De Gaetano A; Pompili M; Riccardi L; Garcovich M; Raffaelli M; Ciccoritti L; Verrastro O; Russo MF; Vecchio FM; Casella G; Casella-Mariolo J; Papa L; Marini PL; Rubino F; le Roux CW; Bornstein S; Mingrone G
    Gut; 2023 Feb; 72(2):392-403. PubMed ID: 35820779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease.
    Maleki I; Aminafshari MR; Taghvaei T; Hosseini V; Rafiei A; Torabizadeh Z; Barzin M; Orang E
    World J Gastroenterol; 2014 Sep; 20(35):12566-73. PubMed ID: 25253959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldo-keto reductase family 1 member B10 is regulated by nucleos(t)ide analogues for chronic hepatitis B.
    Orita N; Kawaguchi K; Honda M; Shimode T; Hayakawa N; Terashima T; Komura T; Nishikawa M; Horii R; Nio K; Shimakami T; Takatori H; Arai K; Sakai Y; Yamashita T; Mizukoshi E; Kaneko S; Kagaya T; Yamashita T
    Biochem Biophys Res Commun; 2023 Sep; 674():133-139. PubMed ID: 37419034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness.
    Liebig S; Stoeckmann N; Geier A; Rau M; Schattenberg JM; Bahr MJ; Manns MP; Jaeckel E; Schulze-Osthoff K; Bantel H
    Clin Transl Gastroenterol; 2019 Aug; 10(8):e00066. PubMed ID: 31397685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver Disease.
    Singh A; Gosai F; Siddiqui MT; Gupta M; Lopez R; Lawitz E; Poordad F; Carey W; McCullough A; Alkhouri N
    J Clin Gastroenterol; 2020; 54(10):891-897. PubMed ID: 32168133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) as a Potential Biomarker for Diagnosis of Hepatocellular Carcinoma.
    Wang Z; Kong L; Zhang R; Yang X; Cao Z; Xu T; Zhang H; Dou Y
    J Hepatocell Carcinoma; 2024; 11():131-143. PubMed ID: 38250307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma Cytokeratin-18 Level As a Novel Biomarker for Liver Fibrosis in Children With Nonalcoholic Fatty Liver Disease.
    Mandelia C; Collyer E; Mansoor S; Lopez R; Lappe S; Nobili V; Alkhouri N
    J Pediatr Gastroenterol Nutr; 2016 Aug; 63(2):181-7. PubMed ID: 26835904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.